Xenon Pharmaceuticals Inc.
XENE
Kedudukan dalam Saham
#4451
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Harga Saham
$36.00
Modal Pasaran
$3.49B
Perubahan (1 hari)
2.63%
Perubahan (1 tahun)
-17.12%
Negara
CA
Perdagangan Xenon Pharmaceuticals Inc. (XENE)
Kategori
Healthcare
Nisbah P/E bagi Xenon Pharmaceuticals Inc. (XENE)
Nisbah P/E pada October 2026 TTM: -7.15
Menurut laporan kewangan dan harga saham terkini Xenon Pharmaceuticals Inc., nisbah P/E semasa (TTM) ialah -7.15. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -16.89.
Sejarah nisbah P/E bagi Xenon Pharmaceuticals Inc. dari 2011 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | -7.15 | -45.11% |
| 2024 | -13.03 | -22.86% |
| 2023 | -16.89 | -11.29% |
| 2022 | -19.04 | 10.20% |
| 2021 | -17.28 | -6.21% |
| 2020 | -18.42 | 125.34% |
| 2019 | -8.18 | 130.09% |
| 2018 | -3.55 | 114.35% |
| 2017 | -1.66 | -68.04% |
| 2016 | -5.19 | -28.84% |
| 2015 | -7.29 | -134.62% |
| 2014 | 21.06 | 165.61% |
| 2013 | 7.93 | -343.99% |
| 2012 | -3.25 | 179.21% |
| 2011 | -1.16 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -502.44% |
US
|
|
| -28.36 | 296.52% |
US
|
|
| -24.57 | 243.50% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -524.08% |
NL
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.